Just something I came across from last week publications. Might interest some....
highlights what big pharma will pay in the Colitis, Crohns sector. If only we could be there.
1 Roche's .1B bet on Roivant drug 2 Roivant struck a deal to sell its potential blockbuster ulcerative colitis drug to Rochefor $7.1 billion, less than a year after acquiring it from Pfizer for much less and following months of news reports hinting that a deal of that size was in the works. The move puts Roche in the TL1A arena with Merck and Sanofi. As to how Roivant plans to spend that cash, CEO Matt Gline said his team will be patient, and it’s too early to tell.
Cell Therapy News/Articles, page-17076
-
- There are more pages in this discussion • 745 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |